Published 2025-01-01
“…
Yongming Xu,1,* Junzhen Wu,1,* Qingqing Jiang,2 Yingying Lv,1 Jin Zhou,1 Zhiyu
Wang,3 Hui Zhao,3
Dongping Du1 1Department of Pain Management Center, Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao
Tong University School of Medicine, Shanghai, People’s Republic of China; 2Department of Neurology, Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao
Tong University School of Medicine, Shanghai, People’s Republic of China; 3Department of Internal Oncology, Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao
Tong University School of Medicine, Shanghai, People’s Republic of China*These authors contributed equally to this
workCorrespondence:
Dongping Du, Department of Pain Management Center, Shanghai Jiao
Tong University Affiliated Sixth People’s Hospital, Shanghai, People’s Republic of China, Tel +86-21-24058896, Email dudp@sjtu.edu.cn Hui Zhao, Department of Neurology, Shanghai Jiao
Tong University Affiliated Sixth People’s Hospital, 600
Yishan Road, Shanghai, 200233, People’s Republic of China, Tel +86-21-24058328, Fax +86-21-240598328, Email zhao-hui@sjtu.edu.cnObjective: Chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect of chemotherapy and it is currently intractable We compared the efficacy of transcutaneous electrical acupoint stimulation (TEAS) against
non-TEAS groups and investigated the variables that predict effective relief of upper extremity pain in cancer survivors with CIPN.Methods: We retrospectively collected data of cancer survivors who developed CIPN between May 2017 to March 2022. …”
Get full text
Article
